Aliso Viejo, California -- Medical device technology company Focal Therapeutics has received $3.8 million in new equity venture capital funding, according to an SEC regulatory filing.
Focal has developed an innovative tissue marker that helps surgeons, oncologists and other clinicians to "clearly identify a surgical site."
Called the BioZorb, the device is implanted by surgeons and delineates the surgical site for tissue removal in three dimensions.
Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds.
A total of 28 investors participate in the offering.
The company is still seeking $1.17 million in additional financing, according to the filing.